Mayne Pharma reports unaudited Q4 and FY26 results

• Sustained growth in Women's Health with BIJUVA® prescriptions up 21%
• Received $14.4 million from Cosette in legal cost recovery
• New Adelaide Apothecary facility to support DistributeRx growth
• FY26 revenue of $383.7 million, gross margin of 65%
• FY26 underlying EBITDA of $31.7 million

Mayne Pharma Group Limited (ASX: MYX) reported unaudited financial and operating results for the fourth quarter and full year ended 30 June 2026. Key highlights include sustained growth in the Women's Health portfolio, with BIJUVA® prescriptions up 21% versus the prior comparable period (pcp). The company received $14.4 million from Cosette in a court-ordered recovery of legal costs and interest. Additionally, Mayne Pharma executed a new lease for its Adelaide Apothecary facility, aiming to increase capacity to over 2.5 million prescriptions per annum to support DistributeRx growth from early 2027. FY26 revenue was $383.7 million, with a gross margin of 65%, and underlying EBITDA was $31.7 million, down 33% from the prior comparable period due to various factors including the Cosette transaction and foreign exchange movements. The company looks forward to providing further updates with its full year results in late August.

FY26 revenue: $383.7 million; FY26 gross margin: 65%; FY26 underlying EBITDA: $31.7 million

Mayne Pharma expects to provide further updates and FY27 outlook with its full year results in late August 2026.